QQQ $ 462.76 $ -0.41 (-0.09 %)
DIA $ 388.38 $ -0.84 (-0.22 %)
SPY $ 533.54 $ -0.65 (-0.12 %)
TLT $ 91.51 $ -1.71 (-1.83 %)
GLD $ 211.60 $ -7.83 (-3.57 %)
$ 0.109
-- x --
-- x --
-- - --
$ 0.09 - $ 3.59
520,069
na
7.89M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 12-10-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-galera-therapeutics-grtx-stock-is-nosediving

Galera Therapeutics shares are trading lower by 34.8% during Monday's session. The company said its shares will be delisted...

 galera-therapeutics-received-a-notice-of-allowance-for-its-us-patent-application-17378852-titled-pentaaza-macrocyclic-ring-complexes-possessing-oral-bioavailability-to-reduce-oral-mucositis-in-head-and-neck-cancer-patients-from-chemoradiation

https://patentcenter.uspto.gov/applications/17378852/ifw/docs

 why-doma-holdings-shares-are-trading-higher-by-around-34-here-are-20-stocks-moving-premarket

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transa...

 galera-therapeutics-q4-eps-010-beats-035-estimate

Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION